Background: The accumulated wisdom is to update the vaccine strain to the expected epidemic
Introduction
Generally, the influenza vaccine strain is updated when there is at least a 4-fold difference in HI titer between the existing vaccine strain and the expected epidemic strain. Public health recommendations are for individuals in high-risk groups to be revaccinated annually [1] ; thus, vaccine efficacy in repeat vaccinees is particularly important. However, the efficacy of repeated vaccination has been difficult to determine definitively: Meta-analysis has shown a statistically significant heterogeneity in the efficacy of repeated vaccination in serology-based field trials [2] , and different studies have draw different conclusions as to the effectiveness of repeated vaccination [3, 4] . To explain this heterogeneity, we introduced the "antigenic distance" hypothesis [5] which states that prior exposure to influenza virus or vaccine can influence the subsequent response depending upon the degree of cross-reactivity among the antigens used in the vaccines and the epidemic influenza strains in each study year (Figure 1) . Using a computer, we showed that this hypothesis offered a parsimonious explanation for the observed variation in repeated vaccination within and between the Hoskins [3] and Keitel [4] repeated vaccination studies ( Figure 2 ). Here we use the antigenic distance hypothesis, and the same computer model, to reason quantitatively about the effects, on repeat vaccinees, of updating the vaccine strain on a less than 4-fold difference.
Methods
The computer model consists of B cells, plasma cells, memory B cells, antibodies, and antigens.
The model captures the essence of the primary and secondary humoral immune response, and the cross-reactive immune response. More details of the model can be found in [5] , full details can be found in the supplemental material of [5] at http://www.pnas.org/, and the software for the simulator is available from http://www.santafe.edu/ dsmith/software/PNAS-model.html. . In all cases, the vaccine dose was 1,000 "units" of non-replicating virus, and the epidemic dose was 500 units of replicating virus.
If the viral load exceeded 1,500 units it was deemed to have passed a "disease threshold" and the simulated individual was considered symptomatic. The attack rate within a group was defined as the proportion of the group in which the viral load exceeded the disease threshold. Vaccine efficacy was defined as
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Results
The attack rate in the non-vaccinated control was 1.0. 2 Attack rates in first-time vaccinees were 0.0, 0.02, 0.55, and 0.83 for homologous, 2-fold, 4-fold, and 8-fold differences, respectively, between the vaccine strain and the actual epidemic strain. Efficacies in repeat vaccinees when the vaccine was updated, and when it was not updated, and for various actual epidemic strains, are shown in Figure 3 . Ratios of efficacy in repeat vaccinees to efficacy in first-time vaccinees ranged from 0.49 to 3.00 ( Figure 3 ).
Updating the vaccine on a 2-fold difference between the existing epidemic strain and the expected epidemic strain resulted in higher predicted vaccine efficacy in repeat vaccinees in all cases compared to when the vaccine was not updated (5
in all cases other than in the case when the actual epidemic strain was the same as the vaccine1 strain). Efficacies when the vaccine was not updated were dependent only on the antigenic distance between the vaccine strain and the actual epidemic strain. When the vaccine was updated to the expected epidemic strain, efficacies in repeat vaccinees depended on the antigenic distances between the actual epidemic strain and both vaccine1 and vaccine2 strains. Repeat vaccine efficacy was higher when there was a triangular configuration between the three strains (for example, when the actual epidemic strain was 4-fold different from both the vaccine1 and vaccine2 strains, and vaccine1 and vaccine2 strains were 2-fold different from each other). Vaccine efficacy in repeat vaccinees exceeded that in first-time vaccinees in some groups (5
) when the vaccine was updated to the expected epidemic strain, and not at all when the vaccine was not updated.
Somewhat surprisingly, for actual epidemic strains closer to vaccine1 than to the expected epidemic strain (strains to the left of vaccine1 in Figure 3 ), the predicted efficacy in repeat vaccinees was higher (5
) when the vaccine was updated than when it remained unchanged-even though leaving the vaccine unchanged would result in a vaccine strain closer to those actual epidemic strains.
Discussion
Updating the vaccine when there is a 2-fold difference between the existing vaccine strain and the expected epidemic strain gave a higher vaccine efficacy in repeat vaccinees than leaving the vaccine unchanged ( Figure 3 ). It is similarly advantageous to update the vaccine on a 4-fold or more difference (data not shown). These results support the current strategy to update the vaccine strain on a 4-fold or more difference between the existing vaccine strain and the expected epidemic strain. Moreover, these results suggest that also updating the vaccine on a 2-fold difference will increase vaccine efficacy in repeat vaccinees compared to leaving the vaccine unchanged.
Influenza epidemics occur most years, and public health recommendations are for at-risk individu-als to be revaccinated annually. Thus, optimizing the vaccine efficacy for a single year by updating the vaccine strain to an expected epidemic strain 2-fold from the existing vaccine is not necessarily the best strategy over multiple years. For example, an advantage of only updating the vaccine when there is at least a 4-fold difference is that there will be less "negative interference" (antigenic sin effect [6, 7] ) from prior vaccinations. Thus, keeping the vaccine unchanged trades off reduced efficacy in repeat vaccinees in the year when the vaccine did not change, for increased efficacy in the subsequent year. To fully assess the tradeoffs for repeat vaccinees in updating the vaccine or not requires examining the effects over multiple years (manuscript in preparation).
A difficulty of updating the vaccine strain on a 2-fold difference in HI titer is that the resolution and reliability of the HI assay are such that only at least a 4-fold difference between strains has typically been considered significant. Beyer and Masurel [8] , and Lapedes and Farber [9] , have used mathematical techniques to address some of the inherent difficulties in obtaining accurate measurements of antigenic distance from HI data. These techniques are investigated further in a manuscript in preparation. 
